|
1
|
Sureda A, Arranz R, Iriondo A, Carreras E,
Lahuerta JJ, García-Conde J, Jarque I, Caballero MD, Ferrà C, López
A, et al: Grupo Español de Linformas/Transplante Autólogo de Médula
Osea Spanish Cooperative Group: Autologous stem-cell
transplantation for Hodgkin's disease: Results and prognostic
factors in 494 patients from the Grupo Español de
Linfomas/Transplante Autólogo de Médula Osea Spanish Cooperative
Group. J Clin Oncol. 19:1395–1404. 2001.PubMed/NCBI
|
|
2
|
Longo DL, Young RC, Wesley M, Hubbard SM,
Duffey PL, Jaffe ES and De Vita VT Jr: Twenty years of MOPP therapy
for Hodgkin's disease. J Clin Oncol. 4:1295–1306. 1986.PubMed/NCBI
|
|
3
|
Prosnitz LR, Farber LR, Kapp DS, Scott J,
Bertino JR, Fischer JJ and Cadman EC: Combined modality therapy for
advanced Hodgkin's disease: 15-year follow-up data. J Clin Oncol.
6:603–612. 1988.PubMed/NCBI
|
|
4
|
Reece DE, Barnett MJ, Connors JM, Fairey
RN, Fay JW, Greer JP, Herzig GP, Herzig RH, Klingemann HG,
LeMaistre CF, et al: Intensive chemotherapy with cyclophosphamide,
carmustine, and etoposide followed by autologous bone marrow
transplantation for relapsed Hodgkin's disease. J Clin Oncol.
9:1871–1879. 1991.PubMed/NCBI
|
|
5
|
Abrahamsen AF, Hannisdal E, Nome O, Holte
H, Hager B, Langholm R and Kvaløy S: Clinical stage I and II
Hodgkin's disease: Long-term results of therapy without laparotomy.
Experience at one institution. Ann Oncol. 7:145–150. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hughes-Davies L, Tarbell NJ, Coleman CN,
Silver B, Shulman LN, Linggood R, Canellos GP and Mauch PM: Stage
IA-IIB Hodgkin's disease: Management and outcome of extensive
thoracic involvement. Int J Radiat Oncol Biol Phys. 39:361–369.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vlachaki MT, Hagemeister FB, Fuller LM,
Besa PC, Hess MA, Brown B, Cabanillas F and Cox JD: Long-term
outcome of treatment for Ann Arbor Stage I Hodgkin's disease:
Prognostic factors for survival and freedom from progression. Int J
Radiat Oncol Biol Phys. 38:593–599. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Smolewski P, Robak T, Krykowski E,
Blasiñska-Morawiec M, Niewiadomska H, Pluzanska A, Chmielowska E
and Zambrano O: Prognostic factors in Hodgkin's disease:
Multivariate analysis of 327 patients from a single institution.
Clin Cancer Res. 6:1150–1160. 2000.PubMed/NCBI
|
|
9
|
Amini RM, Enblad G, Gustavsson A, Ekman T,
Erlanson M, Haapaniemi E and Glimelius B: Treatment outcome in
patients younger than 60 years with advanced stages (IIB-IV) of
Hodgkin's disease: The Swedish National Health Care Programme
experience. Eur J Haematol. 65:379–389. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zapatero A, López MA, Cerezo L, De Vidales
CM, MarIn A and Pérez-Torrubia A: Stage I–III Hodgkin's disease:
Outcome and pattern of failure following treatment with radiation
therapy and chemotherapy in a modern era. Hematology. 7:43–50.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bonfante V, Santoro A, Viviani S, Devizzi
L, Balzarotti M, Soncini F, Zanini M, Valagussa P and Bonadonna G:
Outcome of patients with Hodgkin's disease failing after primary
MOPP-ABVD. J Clin Oncol. 15:528–534. 1997.PubMed/NCBI
|
|
12
|
Bessell EM, Bouliotis G, Armstrong S,
Baddeley J, Haynes AP, O'Connor S, Nicholls-Elliott H and Bradley
M: Long-term survival after treatment for Hodgkin's disease
(1973–2002): Improved survival with successive 10-year cohorts. Br
J Cancer. 107:531–536. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Front D, Bar-Shalom R, Mor M, Haim N,
Epelbaum R, Frenkel A, Gaitini D, Kolodny GM and Israel O: Hodgkin
disease: Prediction of outcome with 67Ga scintigraphy
after one cycle of chemotherapy. Radiology. 210:487–491. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cooper DL, Neumann RD and Caride VJ: A
critical assessment of the prognostic value of gallium-67
scintigraphy in lymphoma. Nuclear Medicine Annual. Freeman L:
(Philadelphia, PA). Lippincott Williams and Wilkins. 211–232.
2000.
|
|
15
|
Delbeke D: Oncological applications of FDG
PET imaging: Brain tumors, colorectal cancer, lymphoma and
melanoma. J Nucl Med. 40:591–603. 1999.PubMed/NCBI
|
|
16
|
Kobe C, Kuhnert G, Kahraman D, Haverkamp
H, Eich HT, Franke M, Persigehl T, Klutmann S, Amthauer H, Bockisch
A, et al: Assessment of tumor size reduction improves outcome
prediction of positron emission tomography/computed tomography
after chemotherapy in advanced-stage Hodgkin lymphoma. J Clin
Oncol. 32:1776–1781. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Iltis A, Eder V, Blasco H, Colombat P and
Sénécal D: Decisional Early Interim
18F-fluoro-2-deoxy-D-glucose positron emission
tomography after two cycles of chemotherapy in de novo Hodgkin
lymphoma. Acta Haematol. 133:172–178. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cheson BD, Horning SJ, Coiffier B, Shipp
MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A,
Hagenbeek A, et al: NCI Sponsored International Working Group:
Report of an international workshop to standardize response
criteria for non-Hodgkin's lymphomas (Review). J Clin Oncol.
17:12441999.PubMed/NCBI
|
|
19
|
Bar-Shalom R, Israel O, Haim N, Leviov M,
Epelbaum R, Frenkel A, Ben-Haim S, Kolodny GM and Front D: Diffuse
lung uptake of Ga-67 after treatment of lymphoma: Is it of clinical
importance? Radiology. 199:473–476. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Even-Sapir E, Bar-Shalom R, Israel O,
Frenkel A, Iosilevsky G, Haim N, Epelbaum R, Gaitini D, Kolodny GM
and Front D: Single-photon emission computed tomography
quantitation of gallium citrate uptake for the differentiation of
lymphoma from benign hilar uptake. J Clin Oncol. 13:942–946.
1995.PubMed/NCBI
|
|
21
|
Eghbali H, Bonichon F, David B, Rojouan J,
Audebert AA, Blanc CM, Zittoun R, Hoerni B and Najman A: Pierre and
Marie Curie Group (GPMC): Combination of ABVD and radiotherapy in
early stages of Hodgkin's disease: Analysis of a series of 94
patients. Radiother Oncol. 18:127–136. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
André M, Brice P, Cazals D, Hennequin C,
Fermé C, Kerneis Y, Rousselot P, Zini JM, Lepage E and Gisselbrecht
C: Results of three courses of adriamycin, bleomycin, vindesine,
and dacarbazine with subtotal nodal irradiation in 189 patients
with nodal Hodgkin's disease (stage I, II and IIIA). Hematol Cell
Ther. 39:59–65. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Brusamolino E, Lunghi F, Orlandi E, Astori
C, Passamonti F, Baraté C, Pagnucco G, Baio A, Franchini P,
Lazzarino M, et al: Treatment of early-stage Hodgkin's disease with
four cycles of ABVD followed by adjuvant radio-therapy: Analysis of
efficacy and long-term toxicity. Haematologica. 85:1032–1039.
2000.PubMed/NCBI
|
|
24
|
Specht L, Nordentoft AM, Cold S, Clausen
NT and Nissen NI: Tumor burden as the most important prognostic
factor in early stage Hodgkin's disease. Relations to other
prognostic factors and implications for choice of treatment.
Cancer. 61:1719–1727. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bonfante V, Santoro A, Viviani S, Zucali
R, Devizzi L, Zanini M, Tesoro Tess JD, Valagussa P, Banfi A and
Bonadonna G: Early stage Hodgkin's disease: Ten-year results of a
non-randomised study with radiotherapy alone or combined with MOPP.
Eur J Cancer. 29A:24–29. 1992.PubMed/NCBI
|
|
26
|
Ansell SM: Hodgkin lymphoma: 2014 update
on diagnosis, risk-stratification and management. Am J Hematol.
89:771–779. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ranson MR, Radford JA, Swindell R, Deakin
DP, Wilkinson PM, Harris M, Johnson RJ and Crowther D: An analysis
of prognostic factors in stage III and IV Hodgkin's disease treated
at a single centre with MVPP. Ann Oncol. 2:423–429. 1991.PubMed/NCBI
|
|
28
|
Fermé C, Bastion Y, Brice P, Lederlin P,
Diviné M, Gabarre J, Assouline D, Ferrant A, Berger F and Lepage E:
Prognosis of patients with advanced Hodgkin's disease: Evaluation
of four prognostic models using 344 patients included in the Group
d'Etudes des Lymphomes de l'Adulte Study. Cancer. 80:1124–1133.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hasenclever D and Diehl V: A prognostic
score for advanced Hodgkin's disease. International Prognostic
Factors Project on Advanced Hodgkin's Disease. N Engl J Med.
339:1506–1514. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Vose JM, Bierman PJ, Anderson JR, Harrison
KA, Dalrymple GV, Byar K, Kessinger A and Armitage JO:
Single-photon emission computed tomography gallium imaging versus
computed tomography: Predictive value in patients undergoing
high-dose chemotherapy and autologous stem-cell transplantation for
non-Hodgkin's lymphoma. J Clin Oncol. 14:2473–2479. 1996.PubMed/NCBI
|
|
31
|
Front D, Israel O and Ben-Haim S: The
dilema of a residual mass in treated lymphoma: The role of
gallium-67 scintigraphy. Nuclear Medicine Annual. 1991.Freeman LM:
(New York, NY). Raven Press. 211–220, 1991.
|
|
32
|
Markova J, Kahraman D, Kobe C, Skopalova
M, Mocikova H, Klaskova K, Dedeckova K, Eich HT, Böll B, Dietlein
M, et al: Role of [18F]-fluoro-2-deoxy-D-glucose
positron emission tomography in early and late therapy assessment
of patients with advanced Hodgkin lymphoma treated with bleomycin,
etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine
and prednisone. Leuk Lymphoma. 53:64–70. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mocikova H, Pytlik R, Markova J,
Steinerova K, Kral Z, Belada D, Trnkova M, Trneny M, Koza V, Mayer
J, et al: Pre-transplant positron emission tomography in patients
with relapsed Hodgkin lymphoma. Leuk Lymphoma. 52:1668–1674. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ionescu I, Brice P, Simon D, Guermazi A,
Leblanc T, Rousselot P, Gossot D, Meignin V, Gisselbrecht C and
Rain JD: Restaging with gallium scan identifies chemosensitive
patients and predicts survival of poor-prognosis mediastinal
Hodgkin's disease patients. Med Oncol. 17:127–134. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Escobar IG, Barrigón DC, Tamayo P, et al:
Prognostic impact of pretransplantation computed tomography and
gallium scans in patients with Hodgkin lymphoma with poor prognosis
undergoing hematopoietic stem cell transplantation. Clin Lymphoma
Myeloma. 7:217–25. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hagemeister FB, Purugganan R, Podoloff DA,
Hess M, Rodriguez MA, McLaughlin P, Swan F Jr, Romaguera JE and
Cabanillas F: The gallium scan predicts relapse in patients with
Hodgkin's disease treated with combined modality therapy. Ann
Oncol. 5(Suppl 2): 59–63. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Delcambre C, Reman O, Henry-Amar M, Peny
AM, Macro M, Cheze S, Génot JY, Tanguy A, Switsers O, Van HL, et
al: Clinical relevance of gallium-67 scintigraphy in lymphoma
before and after therapy. Eur J Nucl Med. 27:176–184. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
King SC, Reiman RJ and Prosnitz LR:
Prognostic importance of restaging gallium scans following
induction chemotherapy for advanced Hodgkin's disease. J Clin
Oncol. 12:306–311. 1994.PubMed/NCBI
|
|
39
|
Ng AK, Bernardo MV, Silver B, Van Den
Abbeele A, Stevenson MA, Fisher DC and Mauch PM: Mid- and post-ABVD
gallium scanning predicts for recurrence in early-stage Hodgkin's
disease. Int J Radiat Oncol Biol Phys. 61:175–184. 2005. View Article : Google Scholar : PubMed/NCBI
|
